Related Experiment Video
Updated: Oct 26, 2025
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
Selective targeting of cancer cells using a hydrogen peroxide-activated Hsp90 inhibitor
Yong Jin Oh1, Sun You Park1, Young Ho Seo1
1College of Pharmacy, Keimyung University, Daegu 704-701, South Korea.
Abstract:
Heat shock protein 90 (Hsp90) plays an important role in cancer cell proliferation, survival, and migration by regulating the maturation and stabilization of numerous oncoproteins. Despite significant efforts in developing Hsp90 inhibitors, none of these have been approved for clinical use, mostly due to toxicity, such as liver, cardiac, and retinal toxicity. To avoid undesirable toxicity, we herein report a hydrogen peroxide-activated Hsp90 inhibitor, Boro-BZide (3), which is capable of selectively targeting cancer cells over normal cells. Boro-BZide (3) can be activated by high levels of hydrogen peroxide, releasing its parent active Hsp90 inhibitor. The mechanism of action was determined by a series of experiments including fluorescence polarization assay, cell viability assay, western blotting, high-pressure liquid chromatography (HPLC), and fluorescence-activated cell sorting (FACS) analysis. These efforts ultimately led to the identification of a novel hydrogen peroxide-activated Hsp90 prodrug with improved therapeutic index, which was less prone to furnish unwanted adverse effects. This hydrogen peroxide-responsive prodrug strategy will be beneficial for overcoming the toxicity hurdles of Hsp90 inhibitors for clinical application.
Insights
Researchers developed a novel hydrogen peroxide-activated Heat shock protein 90 (Hsp90) inhibitor, Boro-BZide. This prodrug selectively targets cancer cells, reducing toxicity and improving the therapeutic index for potential clinical applications.
Area of Science:
- Oncology
- Medicinal Chemistry
- Pharmacology
Background:
- Heat shock protein 90 (Hsp90) is crucial for cancer cell survival and proliferation.
- Existing Hsp90 inhibitors face clinical limitations due to significant toxicities (liver, cardiac, retinal).
Purpose of the Study:
- To develop a novel Hsp90 inhibitor with improved safety and efficacy.
- To design a prodrug activated selectively in cancer cells by hydrogen peroxide.
Main Methods:
- Synthesis and characterization of the hydrogen peroxide-activated Hsp90 inhibitor, Boro-BZide.
- Evaluation of prodrug activation mechanism using fluorescence polarization and HPLC.
- Assessment of anti-cancer activity and toxicity via cell viability assays, western blotting, and FACS analysis.
Main Results:
- Boro-BZide selectively releases its active Hsp90 inhibitor in the presence of high hydrogen peroxide levels characteristic of cancer cells.
- The prodrug demonstrated reduced toxicity compared to conventional Hsp90 inhibitors.
- Improved therapeutic index observed, indicating enhanced efficacy with lower adverse effects.
Conclusions:
- Hydrogen peroxide-activated Hsp90 prodrugs represent a promising strategy to overcome toxicity issues associated with Hsp90 inhibitors.
- Boro-BZide shows potential for clinical application in cancer therapy by offering targeted drug delivery and reduced side effects.
More Related Videos
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
07:25Author Spotlight: Investigating Liver Cancer Pathogenesis Using Patient-Derived Organoids
Published on: August 18, 2023
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...